Adding Venetoclax to Obinutuzumab Prolongs Progression-Free Survival in Previously Untreated CLL
In a phase III trial of patients with previously untreated chronic lymphocytic leukemia (CLL) and co-existing comorbidities, a fixed-duration regimen of obinutuzumab plus venetoclax...
Single-Agent Ibrutinib Improves Survival and Prolongs Time to Next Treatment in Early-Stage CLL
In the double-blind, randomized CLL12 trial, patients with treatment-naïve, early-stage chronic lymphocytic leukemia (CLL) who received single-agent ibrutinib had longer event-free survival (EFS), progression-free...
Ibrutinib Plus Venetoclax Leads to High Rates of MRD Negativity in Frontline CLL
The combination of ibrutinib with venetoclax – two agents that have been approved for the treatment of chronic lymphocytic leukemia (CLL) – led to...
TKIs Linked to Increased Cardiovascular and Arteriothrombotic Events in Chronic-Phase CML
In patients with chronic-phase chronic myeloid leukemia (CML), treatment with tyrosine kinase inhibitors (TKIs) has been shown to increase the risk of cardiovascular and...
Can Women With CML Safely Continue TKIs During Pregnancy?
Most women with chronic myeloid leukemia (CML) who received treatment with tyrosine kinase inhibitors (TKIs) and became pregnant had a normal childbirth, with no...
Single-Agent Acalabrutinib Improves Survival in Relapsed/Refractory Chronic Lymphocytic Leukemia
According to results from the phase III ASCEND trial, treatment with acalabrutinib as a single agent improved progression-free survival (PFS) compared with idelalisib or...
Robert Kreitman: Delayed Versus Concurrent Rituximab in Hairy Cell Leukemia
Robert Kreitman, MD, shares results from a new study suggesting patients with hairy cell leukemia should receive rituximab concurrently with frontline cladribine.
Flumatinib Superior to Imatinib in Chronic-Phase Chronic Myeloid Leukemia
Flumatinib, a second-generation tyrosine kinase inhibitor (TKI), led to more molecular responses that were also deeper, compared with imatinib, in patients with newly diagnosed...
Should Patients With Hairy Cell Leukemia Receive Delayed or Concurrent Rituximab?
For more than 30 years, the standard firstline treatment of hairy cell leukemia (HCL) has been single-agent purine analog therapy, usually cladribine, but a...
Hematologic Malignancies Drive In-Hospital Death Rates
In the past 17 years, the overall rate of in-hospital deaths among patients with hematologic malignancies has decreased by 30 percent, with a corresponding...
Current Issue
August 2020 Volume 6, Issue 10
This issue looks at the rapid expansion of telemedicine, explores access to leukemia treatment in Brazil, and more.